Micronoma Announcements
Micronoma Receives FDA Breakthrough Device Designation for OncobiotaLUNG, A Novel Liquid Biopsy Assay for Lung Carcinoma Detection
The OncobiotaLUNG assay is the first blood microbiome-driven liquid biopsy with proven effectiveness, including identifying cancer in its earliest stages Breakthrough device designation validates Micronoma’s aim to improve the current standard of care for patients...
Micronoma to Provide Oncobiota Solution and Company Updates During JPM Life Science Conference Week 2023
December 14, 2022. SAN DIEGO, Calif.-- Micronoma, the first biotech company offering early cancer detection using a microbiome-driven liquid biopsy platform, today announced that Sandrine Miller-Montgomery, Ph.D., Pharm.D., CEO and Co-founder of Micronoma will...
Research Finds Fungi Ubiquitous in Cancer with Diagnostic Implications
An international collaboration between the Weizmann Institute, UC San Diego, and Micronoma provides the most comprehensive characterization of fungi in cancer to date, discovering synergistic interactions with bacteria and furthering the role of mycobiome as an...
Micronoma Makes Key VP of Business Development Hire
Todd Czerwinski will oversee the development and execution of market access, strategic partnerships and sales as the company rolls out its groundbreaking early cancer diagnosis platform SAN DIEGO, May 24, 2022 — Micronoma, the first cancer detection biotech company...
Micronoma Wins Fourth Innovation Award This Year
Microbiome-driven liquid biopsy company draws international recognition for using innovative technology to enable early cancer detection and improve chances of survivalSAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Micronoma, the first cancer detection biotech company to...
Micronoma Wins Bio-IT World Innovative Practices Award
Machine learning and microbiome-driven liquid biopsy technology draws recognition for improving early cancer diagnosis and chances of survival August 2, 2021 – San Diego, Calif. Micronoma, the first cancer detection biotech company to diagnose cancer at an early...
Micronoma, University of New South Wales Tackle Liver Cancer with $4 Million Grant
Research uses circulating microbiome biomarkers, machine learning for early detection July 20, 2021 – San Diego, Calif. Micronoma, the first cancer detection company to harness tumor-associated circulating microbial biomarkers to diagnose cancer at an early stage...
Micronoma Welcomes Esteemed Clinical Oncologist to Scientific Advisory Board
Jennifer Wargo, M.D., leads research on link between microbiome and cancer treatment and recently co-authored Science review with Micronoma founders San Diego, Calif. (April 6, 2021) - San Diego, Calif. Micronoma, the first cancer detection biotech company that...
Micronoma Raises $3.5 Million in Convertible Note Financing
Investors more than double funding base for cancer microbiome diagnostic company to accelerate go-to-market timeline six months after seed February 17, 2021 -- San Diego, Calif. Micronoma, the first cancer detection biotech company that utilizes signals from the...
Micronoma Expands Executive Team and Operations
SAN DIEGO, Calif., Nov. 5, 2020 /PRNewswire/ -- Micronoma, an early-stage cancer detection biotech company seeking to develop and commercialize a minimally-invasive, unique microbiome-based assay, today announced their company expansion with three key executive...
Micronoma Expands Executive Team and Operations
Innovative early cancer detection company establishes headquarters and adds three key executive positions San Diego, Calif. (November 5, 2020). Micronoma, an early-stage cancer detection biotech company seeking to develop and commercialize a minimally-invasive, unique...
Micronoma Appoints Magda Marquet Chairman of the Board
Biotech maven joins early-stage cancer detection company utilizing innovative microbiome analysis SAN DIEGO, Sept. 30, 2020 /PRNewswire/ -- Micronoma, an early stage cancer-detection start-up seeking to develop and commercialize a minimally-invasive, unique...
Micronoma Launches with $3 Million Seed Funding
For Immediate Release Media Contact: Celia Sepulveda, Celia.Sepulveda@Micronoma.com, 858.337.1326 Micronoma Launches with $3 Million Seed Funding First early cancer-detection company to use microbial biomarkers in diagnostics San Diego, Calif....
UCSD team, and Micronoma founders, publish Nature paper identifying nucleic acid-based, tumor-specific microbial signatures in the blood, suggesting a new diagnostic approach.
Microbiome analyses of blood and tissues suggest cancer diagnostic approach.
Systematic characterization of the cancer microbiome provides the opportunity to develop techniques that exploit non-human, microorganism-derived molecules in the diagnosis of a major human disease.
Micronoma to Present at Biocom’s 10th Annual Global Life Science Partnering Conference
Micronoma will be presenting at Biocom this year. Go to Biocom Micronoma San Diego, CA, USA info@micronoma.comlinkedin

Website Terms of Use, Privacy Policy, and Licenses
Micronoma, INC., CLIA #05D2253538
Oncobiota™ LDT is under development and is currently not available for commercial use in any jurisdiction. Once available under CLIA license, Oncobiota™ will be available in the United States by prescription only.
Contact Us
If you have questions or would like to learn more, please email us at info@micronoma.com or learn about joining our team at Careers.
Micronoma
6342 Ferris Square
San Diego, CA 92121